CTIS2023-506759-51-00招募中1 期
STX-721-101
Scorpion Therapeutics Inc.0 个研究点目标入组 112 人开始时间: 2023年10月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors.Advanced solid tumors including but not limited to gynecologic CancerHead and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10041823Term: Squamous cell carcinoma Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864Breast CancerCTIS2023-504807-94-00Scorpion Therapeutics Inc.220
进行中（未招募）
1 期
A phase Ib study to investigate the safety and effect of BR-003Patients planned for open or percutaneous posterior spinal stabilisation with 4 or 6 pedicle screws with a diameter of 5 to 7.5 mm (inclusive), with or without concomitant posterolateral fusion, vertebral augmentation, intervertebral body fusion devices, osteotomies, and posterior decompression.CTIS2024-516338-37-00SentryX B.V.12
招募中
1 期
A Phase 1 Study of SEA-CD70 in Myeloid MalignanciesCTIS2023-506945-42-00Seagen Inc.140
招募中
1 期
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with pembrolizumab in patients with advanced solid tumorsSelected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).CTIS2024-514746-36-00Oncomatryx Biopharma S.L.120
招募中
1 期
A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumoursocally advanced or metastatic solid tumorsMedDRA version: 21.1Level: PTClassification code: 10028997Term: Neoplasm malignant Class: 100000004864CTIS2023-508764-30-00Chugai Pharmaceutical Co. Ltd.150